| 纯度 | >85% SDS-PAGE |
| 种属 | Human |
| 靶点 | CDC25A |
| Uniprot No | P30304 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-524aa |
| 氨基酸序列 | MELGPEPPHR RRLLFACSPP PASQPVVKAL FGASAAGGLS PVTNLTVTMD QLQGLGSDYE QPLEVKNNSN LQRMGSSEST DSGFCLDSPG PLDSKENLEN PMRRIHSLPQ KLLGCSPALK RSHSDSLDHD IFQLIDPDEN KENEAFEFKK PVRPVSRGCL HSHGLQEGKD LFTQRQNSAP ARMLSSNERD SSEPGNFIPL FTPQSPVTAT LSDEDDGFVD LLDGENLKNE EETPSCMASL WTAPLVMRTT NLDNRCKLFD SPSLCSSSTR SVLKRPERSQ EESPPGSTKR RKSMSGASPK ESTNPEKAHE TLHQSLSLAS SPKGTIENIL DNDPRDLIGD FSKGYLFHTV AGKHQDLKYI SPEIMASVLN GKFANLIKEF VIIDCRYPYE YEGGHIKGAV NLHMEEEVED FLLKKPIVPT DGKRVIVVFH CEFSSERGPR MCRYVRERDR LGNEYPKLHY PELYVLKGGY KEFFMKCQSY CEPPSYRPMH HEDFKEDLKK FRTKSRTWAG EKSKREMYSR LKKL |
| 预测分子量 | 94 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC25A重组蛋白的3篇参考文献，按格式整理：
1. **文献名称**：*"Expression and purification of functional human CDC25A phosphatase in Escherichia coli for cell cycle regulation studies"*
**作者**：Zhang Y, et al.
**摘要**：本研究报道了利用大肠杆菌系统高效表达人源CDC25A重组蛋白的优化方法，通过亲和层析纯化获得高活性蛋白，并验证其通过去磷酸化CDK1/cyclin B复合物调控G2/M期转换的功能。
2. **文献名称**：*"Structural analysis of CDC25A recombinant protein reveals novel insights into substrate recognition"*
**作者**：Molina DM, et al.
**摘要**：通过X射线晶体学解析了重组CDC25A的催化结构域三维结构，揭示了其与磷酸化CDK底物结合的关键氨基酸残基，为设计靶向CDC25A的抗癌药物提供了结构基础。
3. **文献名称**：*"Development of a high-throughput screening assay using recombinant CDC25A phosphatase for anticancer drug discovery"*
**作者**：Chen L, et al.
**摘要**：研究团队建立了基于重组CDC25A蛋白的荧光底物酶活检测体系，成功筛选出多个小分子抑制剂，其中化合物X显示对乳腺癌细胞周期阻滞的显著效果。
(注：以上文献信息为示例性内容，实际引用需根据具体论文调整。)
**Background of CDC25A Recombinant Protein**
CDC25A is a dual-specificity phosphatase belonging to the CDC25 family, which plays a critical role in regulating cell cycle progression. It activates cyclin-dependent kinases (CDKs) by removing inhibitory phosphorylations on Thr14 and Tyr15 residues of CDK1/CDC2 and CDK2. This activity drives transitions through key cell cycle checkpoints, particularly the G1/S and G2/M phases. Dysregulation of CDC25A is closely linked to uncontrolled cell proliferation, genomic instability, and cancer development.
Structurally, CDC25A contains an N-terminal regulatory domain with sites for post-translational modifications (e.g., phosphorylation, ubiquitination) and a C-terminal catalytic domain responsible for phosphatase activity. Its expression and activity are tightly controlled by DNA damage checkpoints. For instance, in response to genotoxic stress, CDC25A is targeted for proteasomal degradation via CHK1/CHK2-mediated phosphorylation, halting cell cycle progression to allow repair.
CDC25A is frequently overexpressed in cancers, including breast, lung, and colorectal tumors, correlating with poor prognosis. This makes it a potential therapeutic target. Recombinant CDC25A protein, produced through *in vitro* expression systems (e.g., *E. coli* or mammalian cells), serves as a tool for studying its biochemical properties, interactions with CDKs, and screening for inhibitors. Such research aids in developing anticancer drugs that selectively block CDC25A’s phosphatase activity or stability.
Studies using recombinant CDC25A have also clarified its role in oncogenic signaling pathways and resistance to chemotherapy, highlighting its dual role as both a cell cycle driver and a stress-response regulator. Ongoing research continues to explore its therapeutic potential in precision oncology.
×
